Nothing Special   »   [go: up one dir, main page]

HRP20211424T1 - Lipidi za formulacije namijenjene unosu terapijskog sredstva - Google Patents

Lipidi za formulacije namijenjene unosu terapijskog sredstva Download PDF

Info

Publication number
HRP20211424T1
HRP20211424T1 HRP20211424TT HRP20211424T HRP20211424T1 HR P20211424 T1 HRP20211424 T1 HR P20211424T1 HR P20211424T T HRP20211424T T HR P20211424TT HR P20211424 T HRP20211424 T HR P20211424T HR P20211424 T1 HRP20211424 T1 HR P20211424T1
Authority
HR
Croatia
Prior art keywords
4alkylene
image
lipid
preparation according
preparation
Prior art date
Application number
HRP20211424TT
Other languages
English (en)
Inventor
Joseph E. Payne
John A. GAUDETTE
Zheng Hou
Mohammad Ahmadian
Lei Yu
Victor Knopov
Violetta AKOPIAN
Priya Karmali
Richard P. WITTE
Neda SAFARZADEH
Wenbin Ying
Jun Zhang
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Publication of HRP20211424T1 publication Critical patent/HRP20211424T1/hr
Publication of HRP20211424T2 publication Critical patent/HRP20211424T2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/14—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated
    • Y10T428/2998—Coated including synthetic resin or polymer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Claims (14)

1. Pripravak odabran od (i) pripravak koji sadrži ionizirani lipid formule I i kationski lipid u liposomu koji sadrži dvosloj molekula lipida; i (ii) pripravak koji sadrži više od jednog ionizirajućeg lipida formule I u liposomu koji sadrži dvosloj molekula lipida, pri čemu ionizabilni lipidni spoj formule I ima sljedeću strukturu: [image] gdje n i m su neovisno 1, 2, 3 ili 4; R1 i R2 su neovisno C10-18alkil ili C12-18alkenil; X je -CH2-, S, O, ili odsutan; L je C1-4alkilen, -S-C1-4alkilen, -O-C1-4alkilen, -O-C(O)-C1-4alkilen, -S(O)2-C1-4alkilen, [image] , ili [image] predstavlja [image] ; ili njegov farmaceutski prihvatljiv solni oblik.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što su n i m 1 ili 2 ili pri čemu X je odsutan, i L je poželjno C1-4alkilen i još poželjnije bira se iz grupe koja se sastoji od -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, i -CH2-CH2-CH2-CH2- ili L [image] je [image] ili [image] predstavlja [image] , i poželjno L je
3. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što X je -CH2- i L se poželjno bira iz grupe koju čine (a) -S-C1-4alkilen i poželjno -S-CH2- ili -S-CH2-CH2-, (b) -S(O)2-C1-4alkilen i poželjno -S (O)2-CH2-CH2-, (c) L je -O-C1-4alkilen i poželjno -O-CH2-CH2- ili -O-CH2-CH2-CH2-, i (d) L je -O-C(O)-C1-4alkilen i poželjno -O-C(O)-CH2-CH2-CH2-.
4. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što X je S i L je ponajprije C1-4alkilen i poželjnije -CH2-CH2-.
5. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što X je O i L je ponajprije C1-4alkilen i poželjnije -CH2-CH2- ili -CH2-CH2-CH2-.
6. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što R1 i R2 su svaki C10-18alkil i poželjno svaki C13alkil, ili gdje su R1 i R2 svaki C12-18alkenil i poželjno svaki C13-17alkenil i poželjnije svaki oleil ili linoleil.
7. Pripravak u skladu s patentnim zahtjevom 1, izvedba (ii), naznačen time što spoj formule I čini 5 do 50 mol % molekula lipida i (ii-1) pripravak poželjno sadrži dva spoja formule I i gdje je molarni omjer dva spoja oko 10:30 do oko 30:10 ili (ii-2) pripravak poželjno nadalje sadrži kationski lipid, pri čemu je kationski lipid poželjnije [image] ili [image] .
8. Pripravak u skladu s patentnim zahtjevom 7, izvedba (ii-2), naznačen time što je kationski lipid 5 do 40 mol % molekula lipida i pri čemu je molarni omjer ionizirajućeg lipida i kationskog lipida poželjno oko 5:35 do oko 35:5.
9. Pripravak u skladu s patentnim zahtjevom 1, izvedba (ii), dodatno sadrži tekući medij pri čemu je tekući medij poželjno pogodan za ubrizgavanje u živi organizam, ili gdje tekući medij poželjno sadrži organsko otapalo, ili pri čemu tekući medij poželjno sadrži vodu i organsko otapalo.
10. Pripravak u skladu s patentnim zahtjevom 1, izvedba (ii), dodatno sadrži ne-vodeni medij ili najmanje jedan fosfolipid ili najmanje jedan lipid konjugiran s PEG-om.
11. Nosač lijekova specifičan za zvjezdaste stanice koji sadrži pripravak u skladu s patentnim zahtjevom 1, izvedba (ii), i količinu ciljajuće molekule specifičnu za zvjezdaste stanice sa strukturom (retinoid)n-spojnica-(retinoid)n, gdje n = 0, 1, 2 ili 3; te gdje spojnica sadrži polietilen glikol (PEG) ili molekulu sličnu PEG-u.
12. Nosač lijekova u skladu s patentnim zahtjevom 11, dodatno sadrži molekulu siRNA.
13. Farmaceutska formulacija koja sadrži nosač lijeka u skladu s patentnim zahtjevom 12 i farmaceutski prihvatljiv nosač ili razrjeđivač.
14. Farmaceutska formulacija u skladu s patentnim zahtjevom 13, naznačena time što je siRNA inkapsulirana u liposom.
HRP20211424TT 2012-06-08 2013-06-07 Lipidi za formulacije namijenjene unosu terapijskog sredstva HRP20211424T2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657480P 2012-06-08 2012-06-08
EP18200656.9A EP3489220B9 (en) 2012-06-08 2013-06-07 Lipids for therapeutic agent delivery formulations

Publications (2)

Publication Number Publication Date
HRP20211424T1 true HRP20211424T1 (hr) 2022-02-04
HRP20211424T2 HRP20211424T2 (hr) 2022-02-18

Family

ID=48626705

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20211424TT HRP20211424T2 (hr) 2012-06-08 2013-06-07 Lipidi za formulacije namijenjene unosu terapijskog sredstva
HRP20181855TT HRP20181855T1 (hr) 2012-06-08 2018-11-07 Lipidi za formulacije namijenjene unosu terapijskog sredstva

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181855TT HRP20181855T1 (hr) 2012-06-08 2018-11-07 Lipidi za formulacije namijenjene unosu terapijskog sredstva

Country Status (22)

Country Link
US (3) US9308267B2 (hr)
EP (2) EP3489220B9 (hr)
JP (1) JP5873604B2 (hr)
KR (1) KR102102801B1 (hr)
CN (1) CN104640841B (hr)
AU (1) AU2013270685B2 (hr)
BR (1) BR112014030714B1 (hr)
CA (1) CA2876148C (hr)
CY (2) CY1120929T1 (hr)
DK (2) DK3489220T3 (hr)
ES (2) ES2697680T3 (hr)
HR (2) HRP20211424T2 (hr)
HU (2) HUE041882T2 (hr)
LT (2) LT3489220T (hr)
PL (2) PL3489220T3 (hr)
PT (2) PT3489220T (hr)
RS (2) RS58108B9 (hr)
RU (1) RU2658007C2 (hr)
SI (2) SI2858974T1 (hr)
TR (1) TR201816986T4 (hr)
TW (1) TWI654997B (hr)
WO (1) WO2013185116A1 (hr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120141576A1 (en) * 2007-03-15 2012-06-07 Benjamin Johnson Treatment of Dermatologic Skin Disorders
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR102014061B1 (ko) 2011-10-03 2019-08-28 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP2015518704A (ja) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 膜タンパク質の産生のための修飾ポリヌクレオチド
RS58108B9 (sr) 2012-06-08 2022-11-30 Nitto Denko Corp Lipidi za formulacije za dostavu terapeutskih agenasa
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
CN105873902B (zh) 2013-11-18 2019-03-08 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
EP3127915B1 (en) 2014-04-02 2020-08-26 Nitto Denko Corporation Rbp-derived targeting molecule and utilization thereof
JP6881813B2 (ja) 2014-04-23 2021-06-02 モデルナティーエックス， インコーポレイテッド 核酸ワクチン
PL3221293T3 (pl) * 2014-11-18 2023-07-10 Arcturus Therapeutics, Inc. Jonizowalny kationowy lipid do dostarczania rna
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20180235995A1 (en) * 2015-02-19 2018-08-23 Nitto Denko Corporation Rna interference therapeutics against ebola virus
JP6480025B2 (ja) * 2015-06-24 2019-03-06 日東電工株式会社 イオン性化合物及び組成物並びにその使用
HUE067372T2 (hu) * 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
HUE053990T2 (hu) 2015-07-22 2021-08-30 Nitto Denko Corp Nanorészecske liofilizált formák készítményei és eljárások
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
ES2924407T3 (es) 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
WO2017106957A1 (en) 2015-12-23 2017-06-29 The University Of British Columbia Lipid-linked prodrugs
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
JP6833456B2 (ja) 2016-11-02 2021-02-24 日東電工株式会社 皮膚線維症処置剤
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3554546A4 (en) 2016-12-14 2021-04-14 Ligandal, Inc. METHODS AND COMPOSITIONS FOR ADMINISTRATION OF NUCLEIC ACID AND PROTEIN PAYLOADS
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
EP4186888A1 (en) 2017-03-15 2023-05-31 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
DK3596042T3 (da) 2017-03-15 2022-04-11 Modernatx Inc Krystalformer af aminolipider
EP3595727A1 (en) 2017-03-15 2020-01-22 ModernaTX, Inc. Lipid nanoparticle formulation
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
EP3696270A4 (en) 2017-10-11 2021-07-07 Nitto Denko Corporation REGULATION OF THE EXPRESSION OF NUCLEIC ACID MOLECULES
CN117105811A (zh) 2017-11-06 2023-11-24 日东电工株式会社 用于递送生物活性分子的膜融合化合物
CN108148870B (zh) * 2018-01-12 2021-09-21 中国人民解放军第四军医大学 一种提高壳聚糖体外转运siRNA效率的方法
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EA202190688A1 (ru) 2018-10-09 2021-06-07 Дзе Юниверсити Оф Бритиш Коламбиа Композиции и системы, содержащие трансфекционно-компетентные везикулы, не содержащие органических растворителей и детергентов, и связанные с ними способы
WO2021055833A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US20230265050A1 (en) * 2020-06-24 2023-08-24 Bristol-Myers Squibb Company Process for synthesizing cationic lipids
IL299263A (en) * 2020-06-24 2023-02-01 Bristol Myers Squibb Co A process for the synthesis of lipids
AU2021328980A1 (en) * 2020-08-20 2023-03-09 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
JP2024500918A (ja) * 2020-12-23 2024-01-10 イーザアールエヌーエー イムノセラピーズ エンヴェー イオン化可能な脂質
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2023044333A1 (en) * 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
WO2023205424A2 (en) * 2022-04-21 2023-10-26 Greenlight Biosciences, Inc. Lipid compositions and methods for nucleic acid delivery
TW202400189A (zh) * 2022-05-20 2024-01-01 比利時商ｅＴｈｅＲＮＡ免疫治療公司 可離子化脂質
WO2024119098A1 (en) * 2022-12-02 2024-06-06 Prime Medicine, Inc. Lipid nanoparticle (lnp) delivery systems and formulations
WO2024162304A1 (ja) * 2023-01-31 2024-08-08 アステラス製薬株式会社 環状アミンを有するカルバモイル脂質又はウレア脂質、それを含む脂質ナノ粒子、及び医薬組成物
CN118666726A (zh) * 2023-03-17 2024-09-20 尧唐(上海)生物科技有限公司 递送治疗剂的脂质化合物及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5994317A (en) * 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
CN1277024A (zh) * 1999-06-11 2000-12-20 克林诺斯生物药品工业有限公司 阳离子脂质体和多脱氧核糖核苷酸的复合物作为药剂的用途
CN101163796B (zh) * 2004-06-07 2012-08-29 普洛体维生物治疗公司 阳离子脂质及应用方法
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
PT2727583T (pt) * 2004-12-22 2021-12-27 Nitto Denko Corp Veículo de fármaco e kit de veículo de fármaco para a inibição da fibrose
JP2006254877A (ja) * 2005-03-18 2006-09-28 Fukuoka Prefecture 糖脂質を含んだキャリア及びそれを用いた遺伝子導入法
JP5902616B2 (ja) * 2010-04-28 2016-04-13 協和発酵キリン株式会社 カチオン性脂質
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
RS59380B1 (sr) * 2011-06-08 2019-11-29 Nitto Denko Corp Jedinjenja za ciljanje isporuke leka i pojačavanje sirnk aktivnosti
SI2773326T1 (sl) 2011-11-04 2019-04-30 Nitto Denko Corporation Metoda za sterilno proizvodnjo delcev lipidno-nukleinske kisline
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
TWI594723B (zh) 2011-12-19 2017-08-11 愛爾康眼科手術激光股份有限公司 用於雷射白內障程序之手術內光學同調斷層掃描成像的影像處理器
RS58108B9 (sr) 2012-06-08 2022-11-30 Nitto Denko Corp Lipidi za formulacije za dostavu terapeutskih agenasa

Also Published As

Publication number Publication date
PL3489220T3 (pl) 2021-11-02
DK2858974T3 (en) 2018-12-03
PT3489220T (pt) 2021-10-22
US20200085957A1 (en) 2020-03-19
HRP20181855T1 (hr) 2018-12-28
TR201816986T4 (tr) 2019-01-21
CN104640841B (zh) 2018-04-13
HUE041882T2 (hu) 2019-06-28
CA2876148C (en) 2021-01-12
WO2013185116A1 (en) 2013-12-12
BR112014030714A2 (pt) 2017-06-27
BR112014030714B1 (pt) 2020-12-22
ES2697680T9 (es) 2022-10-17
HRP20211424T2 (hr) 2022-02-18
CA2876148A1 (en) 2013-12-12
TW201402146A (zh) 2014-01-16
EP3489220A1 (en) 2019-05-29
SI3489220T1 (sl) 2021-11-30
SI2858974T1 (sl) 2019-01-31
TWI654997B (zh) 2019-04-01
EP3489220B1 (en) 2021-08-18
RS62288B9 (sr) 2021-12-31
RU2658007C2 (ru) 2018-06-19
US10441659B2 (en) 2019-10-15
EP3489220B9 (en) 2021-11-10
US9308267B2 (en) 2016-04-12
PT2858974T (pt) 2018-11-29
EP2858974B1 (en) 2018-10-17
RS58108B1 (sr) 2019-02-28
RU2014153658A (ru) 2016-07-27
RS58108B9 (sr) 2022-11-30
AU2013270685B2 (en) 2017-11-30
RS62288B1 (sr) 2021-09-30
DK3489220T3 (da) 2021-09-06
US11103583B2 (en) 2021-08-31
CY1120929T1 (el) 2019-12-11
EP2858974B9 (en) 2022-07-20
EP2858974A1 (en) 2015-04-15
CN104640841A (zh) 2015-05-20
LT2858974T (lt) 2018-12-10
JP5873604B2 (ja) 2016-03-01
KR20150021566A (ko) 2015-03-02
PL2858974T3 (pl) 2019-03-29
ES2697680T3 (es) 2019-01-25
CY1124499T1 (el) 2022-07-22
JP2015523990A (ja) 2015-08-20
US20130330401A1 (en) 2013-12-12
KR102102801B1 (ko) 2020-04-22
HUE056014T2 (hu) 2022-01-28
ES2897216T3 (es) 2022-02-28
AU2013270685A1 (en) 2015-01-29
US20160074514A1 (en) 2016-03-17
LT3489220T (lt) 2021-09-27

Similar Documents

Publication Publication Date Title
HRP20211424T1 (hr) Lipidi za formulacije namijenjene unosu terapijskog sredstva
HRP20191463T1 (hr) Spojevi usmjereni na unos lijeka i poticanje sirna aktivnosti
JP2014529328A5 (hr)
Ilies et al. Lipophilic pyrylium salts in the synthesis of efficient pyridinium-based cationic lipids, gemini surfactants, and lipophilic oligomers for gene delivery
ES2548515T3 (es) Complejos lipídicos recubiertos con PEG y su uso
Huang et al. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties
Rajesh et al. Dramatic influence of the orientation of linker between hydrophilic and hydrophobic lipid moiety in liposomal gene delivery
JP6305343B2 (ja) 活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
ES2859923T3 (es) Compuestos de disulfuro para el suministro de agentes farmacéuticos
Suzuki et al. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates
RS54824B1 (sr) Topikalna formulacija za inhibiciju jak-a
CA2850955C (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
Swain et al. Location, partitioning behavior, and interaction of capsaicin with lipid bilayer membrane: Study using its intrinsic fluorescence
Zhang et al. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer
RU2011146005A (ru) Композиции для лечения воспаления и способы лечения воспаления
WO2019113210A1 (en) Phosphonium-based ionic drug conjugates
Chen et al. Unsaturated cationic ortho esters for endosome permeation in gene delivery
Yadava et al. Curcumin-loaded nanostructure hybrid lipid capsules for co-eradication of breast cancer and cancer stem cells with enhanced anticancer efficacy
Lin et al. Reduced toxicity of liposomal nitrogen mustard prodrug formulation activated by an intracellular ROS feedback mechanism in hematological neoplasm models
Asokan et al. Cytosolic delivery of macromolecules. 3. Synthesis and characterization of acid-sensitive bis-detergents
Nantz et al. The benefit of hydrophobic domain asymmetry on the efficacy of transfection as measured by in vivo imaging
Wehunt et al. Controlled drug-release system based on pH-sensitive chloride-triggerable liposomes
Zakaria et al. Ultra-deformable free fatty acid based nano-carriers for topical delivery of Luteolin: A potential paradigm for management of Methicillin-Resistant Staphylococcus aureus skin infections
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
Huang et al. Asymmetric 1-alkyl-2-acyl phosphatidylcholine: a helper lipid for enhanced non-viral gene delivery